Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.99 USD | +3.10% | +0.67% | -11.01% |
May. 14 | Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises | MT |
May. 14 | Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M | MT |
Financials (USD)
Sales 2024 * | 84.39M | Sales 2025 * | 27.5M | Capitalization | 290M |
---|---|---|---|---|---|
Net income 2024 * | -131M | Net income 2025 * | -226M | EV / Sales 2024 * | 3.44 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 10.5 x |
P/E ratio 2024 * |
-2.48
x | P/E ratio 2025 * |
-1.67
x | Employees | 335 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.34% |
1 day | +3.10% | ||
1 week | +0.67% | ||
1 month | +23.55% | ||
3 months | -24.49% | ||
6 months | +11.99% | ||
Current year | -11.01% |
Managers | Title | Age | Since |
---|---|---|---|
Kristin Yarema
CEO | Chief Executive Officer | 53 | 23-03-31 |
Johanna Mylet
DFI | Director of Finance/CFO | 37 | 15-05-31 |
Mark Gergen
CHM | Chairman | 61 | 18-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marcea Lloyd
BRD | Director/Board Member | 75 | 18-12-31 |
Cynthia Collins
BRD | Director/Board Member | 65 | 21-07-22 |
Mark Gergen
CHM | Chairman | 61 | 18-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.87% | 2 M€ | -25.75% | ||
0.03% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.99 | +3.10% | 173,685 |
24-05-30 | 2.9 | +0.69% | 188,483 |
24-05-29 | 2.88 | +0.70% | 204,175 |
24-05-28 | 2.86 | -3.70% | 367,622 |
24-05-24 | 2.97 | +0.68% | 136,841 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.01% | 290M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- PSTX Stock